

| Número de catálogo | HY583066 |
|---|---|
| Descripción |
Vobarilizumab (HY583066) is a research-grade recombinant antibody targeting CD126. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| Reactividad de especies | Human |
| Aplicaciones | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
| Especie huésped | Human |
| Clonalidad | Monoclonal |
| Isotipo | VH-VH' |
| Objetivo | CD126, IL-6 receptor subunit alpha, IL-6R 1, IL-6R subunit alpha, IL-6R-alpha, IL-6RA, IL6R, Interleukin-6 receptor subunit alpha, Membrane glycoprotein 80, Soluble interleukin-6 receptor subunit alpha, gp80, sIL6R, ALB, Albumin |
| Nivel de endotoxinas | < 10 EU/mg |
| Pureza | >95% as determined by SDS-PAGE. |
| Purificación | Protein A/G purified from cell culture supernatant. |
| Número de acceso | P08887 & P02768 |
| Forma | Liquid |
| Buffer de almacenamiento | 0.01M PBS pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote. |
| Estabilidad y almacenamiento | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Nombres alternativos | Bispecific, (20A11-9mer-ALB11), ALX-0061, 1628814-88-9 |
| Fondo | Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis. |
| Nota | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for Research Grade Vobarilizumab
Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.
Correo: [email protected]


+86-027-65523339
Edificio C, No. 666, Calle Shendunsi, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский